Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Buloxibutid - Vicore Pharma

Next Previous
Drug Profile

Buloxibutid - Vicore Pharma

Alternative Names: C-21; Compound 21 - Vicore Pharma; PROJECT 1; VP 01

Latest Information Update: 28 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vicore Pharma
  • Class Antifibrotics; Antihyperglycaemics; Carbamates; Imidazoles; Small molecules; Sulfones; Thiophenes; Vascular disorder therapies
  • Mechanism of Action Angiotensin type 2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III COVID 2019 infections
  • Phase II Idiopathic pulmonary fibrosis; Raynaud's disease
  • Phase I Diabetes mellitus
  • No development reported Dupuytren's contracture; Fibrosis; Pulmonary arterial hypertension

Most Recent Events

  • 28 May 2025 No recent reports of development identified for phase-I development in Pulmonary-arterial-hypertension(In volunteers) in Sweden (PO)
  • 07 Oct 2024 Phase-II clinical trials in Idiopathic pulmonary fibrosis in USA (PO) (NCT06588686)
  • 07 Sep 2024 Pharmacodynamics data from a phase IIa AIR trial in Idiopathic pulmonary fibrosis presented at the 34th Annual Congress of the European Respiratory Society (ESR-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top